바카라사이트 장난감 Pharmaceutical presents five novel anticancer drug candidates at the AACR-NCI-EORTC 2025 conference

[by Ji, Yong Jun] Hanmi Pharmaceutical unveiled several research outcomes on next-generation therapeutic modalities, including the introduction of its new pipeline candidate, the ‘EP300 Selective Degrader,’ at a prestigious international oncology conference. Expanding beyond its traditional focus on metabolic diseases such as obesity, Hanmi Pharmaceutical is actively advancing research into next-generation modalities that are redefining the current paradigm of cancer treatment.

바카라사이트 장난감 Pharmaceutical announced on October 29 that it presented five non-clinical research findings in poster format at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2025, held in Boston, USA, from October 22 to 26 (local time). The presented studies included the EP300 selective degrader, the SOS1-KRAS interaction inhibitor (development code HM101207), the STING mRNA anticancer candidate, the p53-mRNA anticancer candidate, and the YAP/TAZ-TEAD inhibitor.

The EP300 selective degrader, which drew particular attention during the presentation, is a novel anticancer drug candidate developed using Hanmi Pharmaceutical's proprietary ‘targeted protein degradation (TPD)’ platform technology. The compound functions are based on the principle of ‘synthetic lethality,’ selectively inducing cell death in EP300-dependent cancer cells or those harboring mutations in the CBP gene.

바카라사이트 장난감 Pharmaceutical reported findings showing that the EP300 selective degrader exhibited potent antitumor activity in both EP300-dependent and CBP-mutant cell lines. Moreover, in a prostate cancer xenograft animal model, the compound demonstrated markedly superior tumor-suppressive effects compared with existing first-line treatments and dual EP300/CBP inhibitors.

The company noted that these results attracted considerable attention, as they indicate the potential of the EP300 selective degrader to serve as a novel therapeutic option for EP300-dependent and CBP-mutant cancers. This promise is supported by the compound’s excellent metabolic stability and its potential for oral administration.

The study also confirmed the superior antitumor efficacy of the ‘SOS1-KRAS interaction inhibitor (HM101207)’ compared with competing drugs. HM101207 is a novel inhibitor designed to block the binding between the ‘SOS1,’ a key regulatory protein in the intracellular signal transduction cascade, and KRAS, thereby preventing the activation of oncogenic ‘KRAS mutations’ that drive cancer progression. The candidate previously attracted attention as a promising candidate for global anticancer combination strategies at the ‘RAS-Targeted Drug Development Summit’ in September.

Notably, HM101207 inhibits the binding of the SOS1 protein to various KRAS mutations, thereby attenuating downstream signaling activity and effectively suppressing tumor growth. Furthermore, the compound it anticipated to overcome resistance mechanisms commonly observed with existing therapies, including KRAS G12C inhibitors, receptor tyrosine kinase (RTK) inhibitors, or MAPK signaling pathway inhibitors.

HM101207 also demonstrated strong anticancer synergy when administered in combination with various RAS-off inhibitors. According to the company, HM101207’s high target specificity and minimal drug-drug interaction (DDI) profile, compared with other SOS1 inhibitors currently in development, position it as a promising candidate for use in global anticancer combination therapy strategies.

Hanmi Pharmaceutical also presented research findings on novel immuno-oncology drug candidates developed using its next-generation ‘mRNA platform.’ The STING mRNA anticancer candidate is designed to directly express the STING (Stimulator of Interferon Genes) protein, thereby inducing a potent antitumor immune response. This approach fundamentally reprograms the starting point of the immune response, offering a new therapeutic strategy for tumor control. At the conference, Hanmi Pharmaceutical reported that STING mRNA monotherapy demonstrated significant tumor growth inhibition and favorable safety profiles in colorectal and lung cancer animal models.

The p53 mRNA anticancer candidate, developed using Hanmi Pharmaceutical’s mRNA platform, demonstrated effective inhibition of tumor growth in orthotopic animal models of lung and ovarian cancer. This candidate functions by restoring normal expression of the p53 tumor suppressor protein, thereby inducing apoptosis in cancer cells. Notably, it exhibited strong synergistic effects when used in combination with taxol-based chemotherapy and showed significant antitumor activity in lung and ovarian cancer animal models when administered in combination with Abraxane. In addition, the candidate demonstrated excellent efficacy in paclitaxel-resistant cell lines, indicating its potential for overcoming resistance.

Furthermore, the conference featured a study demonstrating that a YAP/TAZ–TEAD inhibitor exhibited strong growth-inhibitory effects in mesothelioma cell lines harboring Hippo pathway mutations. The compound also significantly suppressed the expression of YAP/TAZ–TEAD target genes in a dose-dependent manner.

“Our company’s anticancer pipeline, which serves as the cornerstone of our new drug development efforts, is expanding its scope of innovation across various modalities, including targeted protein degraders (TPD), messenger ribonucleic acid (mRNA), cell and gene therapy (CGT), antibody-drug conjugates (ADC), and single-domain antibodies (sdAb),” said Choi In-young, Executive Director and Head of Hanmi Pharmaceutical’s R&D Center. “We will continue to harness the full potential of next-generation modalities to create a powerful driving force for the development of global innovative novel drugs.”